Table 2. Comparisons of baseline clinicopathological features based on changes in NC and NP in cohort 2 (N=106).
| Clinicopathological features | N (%) | NC | P value | NP | P value | ||
|---|---|---|---|---|---|---|---|
| Descending | Ascending | Descending | Ascending | ||||
| Age(Mean±SD) | 106 | 61.82±11.28 | 63.94±11.72 | 0.3648 | 59.95±12.15 | 65.27±10.72 | 0.0198 |
| Gender | 0.8730 | 0.4712 | |||||
| Male | 56(52.83%) | 21(53.85%) | 35(52.24%) | 24(57.14%) | 32(50.00%) | ||
| Female | 50(47.17%) | 18(46.15%) | 32(47.76%) | 18(42.86%) | 32(50.00%) | ||
| Tumor stage | 0.0096 | 0.0198 | |||||
| III | 13(12.26%) | 9(23.08%) | 4(5.97%) | 9(21.43%) | 4(6.25%) | ||
| IV | 93(87.74%) | 30(76.92%) | 63(94.03%) | 33(78.57%) | 60(93.75%) | ||
| Primary tumor site | 0.1882 | 0.4884 | |||||
| Gastrointestinal tumors | 60(56.60%) | 21(53.85%) | 39(58.21%) | 24(57.14%) | 36(56.25%) | ||
| Thoracic cancers | 14(13.21%) | 5(12.82%) | 9(13.43%) | 4(9.52%) | 10(15.63%) | ||
| Urogenital neoplasms | 23(21.70%) | 11(28.21%) | 12(17.91%) | 12(28.57%) | 11(17.19%) | ||
| Head and neck neoplasm | 6(5.66%) | 0(0.00%) | 6(8.96%) | 1(2.38%) | 5(7.81%) | ||
| Other tumors | 3(2.83%) | 2(5.13%) | 1(1.49%) | 1(2.38%) | 2(3.13%) | ||
| Palliative care | <0.001 | 0.0025 | |||||
| PCR | 52(49.06%) | 9(23.08%) | 43(64.18%) | 13(30.95%) | 39(60.93%) | ||
| BSC | 54(50.94%) | 30(76.92%) | 24(35.82%) | 29(69.05%) | 25(39.06%) | ||
| Family history | 0.1718 | 0.1872 | |||||
| No | 73(68.87%) | 30(76.92%) | 43(64.18%) | 32(76.19%) | 41(64.06%) | ||
| Yes | 33(31.13%) | 9(23.08%) | 24(35.82%) | 10(23.81%) | 23(35.94%) | ||
| ECOG score | 0.1292 | 0.1741 | |||||
| <3 | 81(76.42%) | 33(84.62%) | 48(71.64%) | 35(83.33%) | 46(71.88%) | ||
| >=3 | 25(23.58%) | 6(15.38%) | 19(28.36%) | 7(16.67%) | 18(28.13%) | ||
| Comorbidity | 0.4552 | 0.6747 | |||||
| No | 63(59.43%) | 25(64.10%) | 38(56.72%) | 26(61.90%) | 37(57.81%) | ||
| Yes | 43(40.57%) | 14(35.90%) | 29(43.28%) | 16(38.10%) | 27(42.19%) | ||
| Nutritional status | 0.2475 | 0.6494 | |||||
| Normal | 42(39.62%) | 19(48.72%) | 23(34.33%) | 19(45.24%) | 23(35.94%) | ||
| Abnormal | 63(59.43%) | 20(51.28%) | 43(64.18%) | 23(54.76%) | 40(62.50%) | ||
| Unknown | 1(0.94%) | 0(0.00%) | 1(1.49%) | 0(0.00%) | 1(1.56%) | ||
Abbreviation: NC, neutrophil counts; NP, neutrophil percentages; SD, Standard Deviation; BSC, best supportive care; PCR, palliative chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group.